Clarity Pharmaceuticals (ASX:CU6) received a fast track designation from the US Food and Drug Administration for its imaging agent Copper-67-SAR-bisPSMA for the potential treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been previously treated with androgen receptor pathway inhibition, according to a Wednesday Australian bourse filing.
Clarity earlier received two fast track designations for the diagnostic Copper-64-SAR-bisPSMA in prostate cancer patients.
The designation was granted based on the preliminary results to date from the phase 1 and 2a study, which is investigating the safety and efficacy of copper-67-SAR-bisPSMA for the treatment of prostate cancer patients.
It will allow for a faster review process once Clarity submits its product approval applications, per the filing.
The trial is currently advancing through the highest dose group where participants were administered multiple doses of 12 gigabecquerels of copper-67-SAR-bisPSMA and recruitment into the fourth group has been completed.
SAR-bisPSMA connects two prostate-specific membrane antigen-targeting agents to the firm's proprietary sarcophagine technology which securely holds copper isotopes.
The firm's shares rose almost 3% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。